QuidelOrtho (QDEL) Expected to Announce Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL) will likely be releasing its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect QuidelOrtho to post earnings of $0.37 per share and revenue of $658.4120 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.43 by $0.03. The firm had revenue of $723.60 million during the quarter, compared to analyst estimates of $699.80 million. QuidelOrtho had a negative net margin of 41.46% and a positive return on equity of 5.91%. QuidelOrtho’s revenue was up 2.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 EPS. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

QuidelOrtho Stock Performance

NASDAQ QDEL opened at $12.64 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.50 and a debt-to-equity ratio of 1.29. The firm has a market cap of $860.72 million, a PE ratio of -0.76 and a beta of 0.75. The company has a 50 day moving average price of $16.80 and a 200 day moving average price of $23.93. QuidelOrtho has a 52 week low of $10.86 and a 52 week high of $38.99.

Insiders Place Their Bets

In other QuidelOrtho news, CEO Brian J. Blaser acquired 10,540 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were acquired at an average cost of $23.59 per share, with a total value of $248,638.60. Following the acquisition, the chief executive officer directly owned 40,073 shares of the company’s stock, valued at approximately $945,322.07. The trade was a 35.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Matthew Strobeck acquired 10,000 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was acquired at an average cost of $23.96 per share, for a total transaction of $239,600.00. Following the completion of the acquisition, the director directly owned 27,775 shares in the company, valued at approximately $665,489. The trade was a 56.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 23,910 shares of company stock valued at $567,973. Insiders own 0.79% of the company’s stock.

Institutional Trading of QuidelOrtho

Several large investors have recently made changes to their positions in the business. California State Teachers Retirement System boosted its holdings in shares of QuidelOrtho by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock valued at $1,792,000 after acquiring an additional 725 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after purchasing an additional 886 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of QuidelOrtho by 0.7% in the 4th quarter. JPMorgan Chase & Co. now owns 126,404 shares of the company’s stock valued at $3,610,000 after purchasing an additional 903 shares during the period. Larson Financial Group LLC lifted its stake in shares of QuidelOrtho by 322.2% in the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares during the period. Finally, Comerica Bank lifted its stake in shares of QuidelOrtho by 1.8% in the 3rd quarter. Comerica Bank now owns 77,921 shares of the company’s stock valued at $2,295,000 after purchasing an additional 1,349 shares during the period. 99.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on QDEL. UBS Group reduced their price objective on shares of QuidelOrtho from $30.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, April 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Sunday, April 12th. Zacks Research downgraded shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Finally, Citigroup boosted their target price on shares of QuidelOrtho from $23.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $28.25.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.